|Bid||6,500.00 x 100|
|Ask||0.00 x 100|
|Day's range||6,514.57 - 6,514.57|
|52-week range||4,766.00 - 8,700.00|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||25.85|
|Earnings date||19 Oct 2021 - 25 Oct 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Biogen's new — and controversial — Alzheimer's drug, Adhulem, made a modest $2 million in revenue in the first several weeks after its...
BIIB earnings call for the period ending June 30, 2021.
Myles Udland, Brian Sozzi, and Julie Hyman breakdown more Q2 earnings, which include: AT&T stock rising as the company topped estimates due to a push from wireless subscriber additions, Crocs beating earnings as sales growth accelerates from continued customer demand, Didi experiencing more scrutiny as China weighs serious penalties, and Biogen reporting strong Q2 earnings despite criticism of its new Alzheimer’s drug.